Otto von Guericke

Jul 18, 2024 | academic.oup.com | Adaptive Biotechnologies |Otto von Guericke |Heinrich Heine |LMU Klinikum

Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). MS patients have elevated titers of EBV-specific antibodies in serum and show signs of CNS damage only after EBV infection. Regarding CD8+ T-cells, an elevated but ineffective response to EBV was suggested in MS patients, who present with a broader MHC-I-restricted EBV-specific T-cell receptor beta chain (TRB) repertoire compared to controls.

Aug 14, 2023 | scitechdaily.com | Otto von Guericke

A cross-disciplinary group of scientists at the Otto-von-Guericke University in Magdeburg has unveiled a new understanding of how inflammatory mediators of pathogen defense can remotely drive cancer cells into death – an important contribution to improving cancer immunotherapies. Modern immunotherapies enhance the body’s natural ability to combat cancer by activating the immune system’s killer T cells that can specifically target and eliminate cancer cells.

Feb 3, 2023 | frontiersin.org | Otto von Guericke

Khaldoon O. Al-Nosairy1*, Alexander Duscha2, Henrike Buhr1, Antonia Lipp2, Christiane Desel2, Tobias Hegelmaier2, Hagen Thieme1, Aiden Haghikia2 and Michael B.